Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

AIRNA

Clinical Phase 1

Profile checked Oct 10, 2026

Keywords: Alpha 1 Antitrypsin Deficiency

$310.0MRaised (2 yrs)1Trials (company is sponsor)

Timeline

Apr 1, 2026 Raise Private equity round — Series B: $155M (total, as published), announced Apr 1, 2026. Source: company's own press page. source ↗
Mar 17, 2026 Trial start Phase 1: A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD) source ↗
Apr 1, 2025 Raise Private equity round — Series B: $155M (total, as published), announced Apr 1, 2025. Source: company's own press page. source ↗

Upcoming milestones

2028-11 (ESTIMATED) · Phase 1 · A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD) · NCT07431112

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $310.0M. Last 2 years.

Apr 1, 2026 Private equity round — Series B: $155M (total, as published), announced Apr 1, 2026. Source: company's own press page. source ↗
Apr 1, 2025 Private equity round — Series B: $155M (total, as published), announced Apr 1, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07431112	A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)	Phase 1	Recruiting	Mar 17, 2026	2028-11 (estimated)